Biopharmaceutical News and Research

RSS

Myriad and Clovis ink deal on FDA-approved BRACAnalysis CDx test to identify patients with germline BRCA mutations for rucaparib treatment

Myriad Genetics, Inc. and Clovis Oncology, Inc. have announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis’ PARP inhibitor, Rubraca. Financial terms of the deal were not disclosed.

3 May 2017

Shire and Parion Sciences to collaborate on P-321 for ophthalmic indications

Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.

3 May 2017

New analysis shows high mortality and financial burden for pulmonary disease due to non-tuberculosis mycobacterium (NTM)

The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.

2 May 2017

Antibody treatment protects non-human primates against deadly Marburg and Ravn viruses

An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to the latest findings of a collaborative team from The University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical Inc., and Vanderbilt University. The findings are now available in Science Translational Medicine.

6 Apr 2017

Experimental treatment cures Marburg and Ravn virus infection in animals

Scientists funded by the National Institutes of Health have found that an experimental treatment cured 100 percent of guinea pigs and rhesus monkeys in late stages of infection with lethal levels of Marburg and Ravn viruses, relatives of the Ebola virus.

5 Apr 2017

CenterWatch 2017 Global Investigative Site Relationship Survey ranks PAREXEL among top five CROs

PAREXEL International Corporation, a leading global biopharmaceutical services organisation, today announced that it was named a top contract research organisation in the CenterWatch 2017 Global Investigative Site Relationship Survey. The survey recognises CROs that have high-quality working relationships with investigative sites.

From Parexel 5 Apr 2017

Case Western Reserve and Q2 Pharma partner to develop antivirulence agents that disarm superbugs

Case Western Reserve University and Q2 Pharma Ltd., an Israeli biopharmaceutical company, have signed a two-year option to license small molecule, antivirulence technology to potentially treat bacterial infections such as methicillin-resistant staphylococcus aureus (MRSA), the first known scientific effort of its kind.

31 Mar 2017

PAREXEL introduces patient sensor solution for improved data collection in clinical trials

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of its patient sensor solution, a new offering that securely captures, transmits, stores, and visualises study subject data in clinical trials.

From Parexel 31 Mar 2017

New system incorporating MALS and AF4 launched by Postnova Analytics

Postnova Analytics announces the AF2000 MALS - a new temperature controlled Flow Field-Flow Fractionation - MALS system developed to provided unmatched separation, characterization and fractionation of biopharmaceutical proteins.

From Postnova Analytics 29 Mar 2017

Sartorius to Acquire Real-Time Live-Cell Analysis Pioneer and Leader Essen BioScience

Sartorius, a leading partner to the biopharmaceutical industry and laboratories, today signed an agreement to acquire U.S. based Essen BioScience Inc.,

From Sartorius 6 Mar 2017

Blocking protein found on surface of ovarian cancer cells could prevent metastasis, research suggests

Blocking a protein found on the surface of ovarian cancer cells could prevent or reduce the spread of the disease to other organs, according to new research at the University of Illinois at Chicago.

3 Mar 2017

UAB researchers developing new peptide that may help combat familial hypercholesterolemia

Researchers at the University of Alabama at Birmingham are developing and testing a new peptide that they hope will lead to better treatment options for familial hypercholesterolemia.

22 Feb 2017

PAREXEL introduces new mobile app to improve clinical trial supply management processes, increase patient safety

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today launched a mobile app for the ClinPhone RTSM (randomisation and trial supply management) service.

15 Feb 2017

Study to investigate effectiveness of novel combination treatment for eradicating HIV

A Case Western Reserve University School of Medicine researcher has received a $2.5 million grant from Gilead Sciences, a California-based biopharmaceutical company, to see if two so-far separately-used AIDS treatments are even more effective when used as a pair.

1 Feb 2017

Enzyme identified in baker's yeast can efficiently annihilate leukemia cells

An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.

18 Jan 2017

NCI launches new drug formulary to help expedite use of agents in clinical studies

The National Cancer Institute today launched a new drug formulary (the "NCI Formulary") that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.

11 Jan 2017

DaVita releases recap of 2016 accomplishments

DaVita Inc., a leading independent medical group and a leading provider of kidney care services in the United States, today released a recap of major accomplishments for the company in 2016, marking its 16th year bringing quality of life to patients and teammates around the world.

30 Dec 2016

Leading journal publishes article about ciliate lipases as therapeutic candidates for oral treatment of EPI

Cilian AG, a biopharmaceutical company focused on the development of subunit vaccines, enzymes and monoclonal antibodies, announces that the European Journal of Gastroenterology & Hepatology, the international, peer-reviewed, online publication journal, has published an article entitled: Novel ciliate lipases for enzyme replacement during exocrine pancreatic insufficiency.

20 Dec 2016

How can we tackle antimicrobial resistance?

Antimicrobial resistance happens when bugs, like bacteria, fungi or viruses, change, or evolve, when they’re exposed to drugs, like antibiotics, antifungals, or antivirals. Bugs that develop antimicrobial resistance are sometimes referred to as ‘superbugs’.